O4 Hubs detail
O4 Detail Hero Banner

Drug Pipeline Insights Report

3 new first-in-class therapies coming

See how innovation is driving the latest product development.

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx­ | Published: April 2023

O4 1 Column (Full)
O4 Text Component

2023 will be a busy year for new pharmaceutical treatments.

O4 2 Columns (1/2 - 1/2)
O4 1 Column (Full)
O4 Text Component

Welcome to the next issue of Drugs to Watch for 2023

In this Drug Pipeline Insights Report, we review:

  • Two respiratory syncytial virus (RSV) vaccines
  • A gene therapy for Duchenne muscular dystrophy (DMD)
  • First FDA-approved treatment for nonalcoholic steatohepatitis (NASH), a rare liver disease

Download now

Don't want to read the full report? Download the brief summary.

View summary

Related Content

O4 Complex Card

4 new drugs to watch this year

Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.
O4 Complex Card

Which rules will impact pharmacy in 2023?

2023 is already a busy year for pharmacy regulation. Read about the latest regulations that could impact you and your pharmacy benefit plan.
O4 Complex Card

3 new drugs to watch this fall

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.